IRLA

IRulya Therapeutics Inc.

IRLA | NASDAQ

Price Alert Chart Builder DCF Calculator

$32.06

-$0.89 (-2.70%)

Nov 2, 2026, 1:38 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.70%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

37.3

+3.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #591/1028 (Top 57%)

Full Analysis

Key Statistics

Market Data

Market Cap $32.61M

1D Range

31.02 33.00

52W Range

16.00 880.00

Valuation (TTM)

PE -0.48

PB 0.31

EV/EBITDA 1.14

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $70.00

Cash Flow

FCF Yield -140.3%

SBC Adj. FCF Yield -187.5%

SBC Impact -33.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 51.3% | 36.2%

FCF 3Y | 5Y -25.5% | 4.2%

Returns

ROA -74.6%

ROE -413.3%

ROIC -104.6%

Financial Health

Net Cash

$115.98M

Current Ratio 14.52

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension a...

Sector Healthcare

Industry Biotechnology

Employees 38

IPO Date May 9, 2019

Website quincetx.com

Fiscal Year January - December

Full Company Profile

Latest News

18 days ago · globenewswire.com

IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious underserved diseases, today announced that senior management will participate in a Fireside Chat at the Craig-Hallum Biotech Catalyst Conference on Thursday, October 22, 2026.

24 days ago · globenewswire.com

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R.

27 days ago · seekingalpha.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

1 month ago · seekingalpha.com

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

2 months ago · globenewswire.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET.

2 months ago · globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:

3 months ago · globenewswire.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$70.00

Upside

+118.34%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞